

Editorial

Open Access

The Renin-Angiotensin System: Is there a Limit to where it Goes?

Flávio de Castro Magalhães¹, Valério Garrone Barauna^{2*}

¹Programa Multicêntrico de Pós-Graduação em Ciências Fisiológicas, Brazilian Physiological Society, Federal University of the Jequitinhonha and Mucuri Valleys, Diamantina, Brazil

²Department of Physiological Sciences, Federal University of Espirito Santo, Vitoria, Brazil

***Corresponding Author:** Valerio Garrone Barauna, Department of Physiological Sciences, Federal University of Espirito Santo, Vitoria, Brazil. E-mail: barauna2@gmail.com

Citation: Valerio Garrone Barauna et al. (2017), The Renin-Angiotensin System: Is there a Limit to where it Goes?. Int J Car & Hear Heal. 1:1, 7-8

Copyright: ©2017 Valerio Garrone Barauna et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

Received August 12, 2017; **Accepted** August 19, 2017; **Published** August 22, 2017

Introduction

The renin angiotensin system (RAS) has been extensively studied since the Finnish physiologist Robert Tigerstedt described in 1898 that arterial pressure was elevated upon infusion of kidney extracts containing the “pressor substance” renin in anesthetized animals [1]. Its understanding is of unquestionable relevance for the cardiovascular homeostasis since pharmacological agents (–sartans (AT1R blockers) or –pril (ACE inhibitors)) that blunt actions of the RAS has been extensively used in the management of various cardiovascular conditions and its benefits goes beyond the blood pressure reduction effects [2]. More recently, therapeutical strategies have also reached the inhibition of upstream molecules as the discoveries of renin inhibitors.

Although pharmacological therapies have been developed based on the classical view of the RAS, in which Ang II acts as the effector molecule of the system by its binding to the AT1 receptor, recent discoveries have been made regarding other functions within the RAS. Perhaps two of the most relevant discovery are: 1) the activation of molecules of the RAS independent of ligands by hemodynamic forces; and 2) the discovery of biased ligands to the AT1R that beyond blocking Ang II effects also elicits specific intracellular signaling.

The first evidence of AT1R activation by mechanical forces, independently of its ligand, was demonstrated in cardiomyocytes cells stimulated by stretch by Zou et al. [3]. Later it was found that this activation led to non-canonical AT1 receptor signaling, independent of the classical Gq activation but dependent of arrestin-2 recruitment and it has been shown to have beneficial effects on the heart beyond the blockade of Ang II-mediated effects [4].

Later, in 2013, Ramkhalawon et al. [5] and us [6,7] showed that the AT1R could also be activated by another mechanical stress, the shear stress, which shed light into a new possible molecular mechanism AT1R activation. Also as stated by Ramkhalawon et

al. [5] and by us on our studies, although both stretch and shear stress are mechanical stresses, the molecular mechanisms that transduce these stimuli may differ greatly and both studies support that hypothesis. Now that the phenomenon of AT1R activation by shear stress has been elucidated, its biological relevance should be stressed. Recently, Carneiro et al. [5] did a step forward this understanding and showed that arrestin-2 recruitment, independently of the G-protein activation, is a key molecule in the NO generation by shear stress in endothelial cells. Besides the AT1R activation, we have also shown that ACE can also act as a mechanosensor to shear stress[8].

The second advance regarding RAS were the development of biased ligand to the AT1R (mainly the TRVs), which are into the phase II clinical trial of its developmental stage to treat patients with acute heart failure but so far any benefit over placebo with regards to the primary composite endpoint has been found [9]. Biased ligands are by definition molecules that specifically activate or block a subset of intracellular signaling repertoire. In this sense, TRV120027 targets the AT1R in such a way that blocks of the G-protein mediated adverse effects of Ang II while simultaneously unmasks beneficial pharmacology mediated by beta-arrestin. Its benefits to heart and kidney were already clearly demonstrated in animal models by us and others [10–12].

It is well known that AT1 receptor activation by its ligand angiotensin II has a central role to the pathogenesis of cardiovascular diseases through vascular inflammation, increased reactive oxygen species production, endothelial dysfunction and atherosclerosis. One possible mechanism of such response is the increase in NADPH activation and increase in reactive oxygen species (ROS) production that directly scavenges nitric oxide (NO) as well as decrease eNOS function by its uncoupling.

We are currently investigating the dichotomist possibility of AT1R activation by TRV versus Ang II in the vascular tissue. Our

research focus on the understanding of the effects of biased ligands AT1R, such as TRVs, on vascular function since this molecule has been shown to activate the AKT/PI3K/eNOS pathway. We believe that our findings will contribute to future studies towards the understanding of the RAS pathophysiological real meaning.

References

1. J.E. Hall, Historical perspective of the renin-angiotensin system., *Mol. Biotechnol.* 24 (2003) 27–39.
2. S.J. Cleland, J.L. Reid, The renin-angiotensin system and the heart: a historical review., *Heart.* 76 (1996) 7–12.
3. Y. Zou, H. Akazawa, Y. Qin, M. Sano, H. Takano, T. Minamino, et al., Mechanical stress activates angiotensin II type 1 receptor without the involvement of angiotensin II., *Nat. Cell Biol.* 6 (2004) 499–506.
4. K. Rakesh, B. Yoo, I.-M. Kim, N. Salazar, K. Kim, H.A. Rockman, beta-Arrestin-biased agonism of the angiotensin receptor induced by mechanical stress., *Sci. Signal.* 3 (2010) ra46.
5. B. Ramkhalawon, D. Rivas, S. Lehoux, Shear stress activates extracellular signal-regulated kinase 1/2 via the angiotensin II type 1 receptor., *FASEB J.* (2013) 1–9.
6. V.G. Barauna, F.C. Magalhaes, L.C.G. Campos, R.I. Reis, S.P. Kunapuli, C.M. Costa-Neto, et al., Shear stress-induced Ang II AT1 receptor activation: G-protein dependent and independent mechanisms., *Biochem. Biophys. Res. Commun.* 434 (2013) 647–52.
7. V.G. Barauna, P.R. Mantuan, F.C. Magalhães, L.C.G. Campos, J.E. Krieger, AT1 receptor blocker potentiates shear-stress induced nitric oxide production via modulation of eNOS phosphorylation of residues Thr(495) and Ser(1177.)., *Biochem. Biophys. Res. Commun.* 441 (2013) 713–9.
8. V.G. Barauna, L.C.G. Campos, A.A. Miyakawa, J.E. Krieger, ACE as a mechanosensor to shear stress influences the control of its own regulation via phosphorylation of cytoplasmic Ser(1270)., *PLoS One.* 6 (2011) e22803.
9. P.S. Pang, J. Butler, S.P. Collins, G. Cotter, B.A. Davison, J.A. Ezekowitz, et al., Biased ligand of the angiotensin II type 1 receptor in patients with acute heart failure: a randomized, double-blind, placebo-controlled, phase IIB, dose ranging trial (BLAST-AHF)., *Eur. Heart J.* (2017) 1–10.
10. G. Boerrigter, M.W. Lark, E.J. Whalen, D.G. Soergel, J.D. Violin, J.C. Burnett, Cardiorenal Actions of TRV120027, a Novel, {beta}-Arrestin-Biased Ligand at the Angiotensin II Type I Receptor, in Healthy and Heart Failure Canines: A Novel Therapeutic Strategy for Acute Heart Failure., *Circ. Heart Fail.* (2011) 120027–120027.
11. G. Boerrigter, D.G. Soergel, J.D. Violin, M.W. Lark, J.C. Burnett, TRV120027, a novel β -arrestin biased ligand at the angiotensin II type I receptor, unloads the heart and maintains renal function when added to furosemide in experimental heart failure., *Circ. Heart Fail.* 5 (2012) 627–34.
12. C.P. Carneiro de Moraes, J.Z. Polidoro, D.L. Ralph, T.D. Pessoa, M. Oliveira-Souza, V.G.V.G. Barauna, et al., Proximal tubule NHE3 activity is inhibited by beta-arrestin-biased angiotensin II type 1 receptor signaling, *Am. J. Physiol. - Cell Physiol.* 309 (2015) C541–C550.